drugset / Trial / NCT02557594

Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers

NCT02557594

Phase 1 Completed 36 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This Phase I clinical study is to evaluate the safety and pharmacokinetics of DA-2802 319mg and Viread 300mg after a single oral dose in healthy male volunteers.

Timeline

Start
2015-10-06
Primary completion
2015-11-17
Completion
2016-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-2802 Unknown 319 mg Oral
Subject Tenofovir disoproxil fumarate Small molecule 300 mg Oral

Indications

No indication recorded.